Comparative Pharmacology
Head-to-head clinical analysis: LITFULO versus VONJO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LITFULO versus VONJO.
LITFULO vs VONJO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Litfulo (ritlecitinib) is a Janus kinase (JAK) inhibitor that selectively inhibits JAK3 and to a lesser extent TEC family kinases, thereby modulating the signaling pathways involved in the immune response.
Pacritinib is a Janus kinase 2 (JAK2) and interleukin-1 receptor-associated kinase 1 (IRAK1) inhibitor. It inhibits JAK2 and mutant JAK2V617F, reducing cytokine signaling and proliferation of malignant cells.
50 mg orally once daily, with or without food.
400 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 40–60 h), supporting once-daily or twice-daily dosing with steady-state achieved within 10–14 days.
Terminal elimination half-life approximately 40–60 hours; allows once-daily dosing. Steady-state achieved in 8–14 days.
Primarily excreted unchanged in feces (≈66%) via biliary secretion, with renal excretion accounting for ≈23% as unchanged drug and metabolites; <1% excreted in urine as unchanged parent compound.
Primarily metabolized by the liver via CYP3A4 and CYP2C8; ~90% eliminated in feces as metabolites, ~10% in urine as unchanged drug and metabolites.
Category C
Category C
JAK Inhibitor
JAK Inhibitor